Amarin Corp Ads (AMRN)
$4.01 0.16 (3.84%)
19:52 EDT AMRN Stock Quote Delayed 30 Minutes
Previous Close $4.01
Market Cap 1.18B
PE Ratio -
Volume (Avg. Vol.) 8.70M
Day's Range 3.92 - 4.11
52-Week Range 3.91 - 26.12
Dividend & Yield N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp Ads News
- From InvestorPlace
- From the Web
The biggest unknown weighing on Amarin stock is how long the decision to take Vascepa will be up to patients, rather than experts.
Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020.
Amarin stock is struggling, and that's been the case even before the stock market pulled back. Here's how AMRN looks now.
Investors should feel confident adding Amarin stock to their portfolios, especially because it has the government on its side.
As Vascepa's competition dwindles and the drug gains market share, AMRN stock could be in for some significant upside in 2020.
Amarin stock has some potential, but there are also many risks involved. Therefore, it doesn’t hurt to wait if you really want to buy these shares.
AMRN stock is likely fairly priced -- possibly even overpriced -- right now. It might take more time before analysts and the company actually raise their revenue and cash flow estimates based on patient uptake of Vascepa.
AstraZeneca out of the way. Plus, some key technical resistance is also dismantled, so it’s time to go long AMRN stock today.
During the past year, Amarin stock has been a laggard. But this could change in 2020 with the company's new drug poised for long-term growth.
Amarin stock has faded in recent weeks despite a spate of good news. That response suggests AMRN shares may have further to fall.
AstraZeneca is stopping a large clinical study of its fish-oil-derived heart drug, Epanova. That’s good news for Amarin and Amarin stock.
Amarin stock is set for growth with Vascepa approval and sales outlook for 2020 predicting revenue will eventually hit billions of dollars
Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.
By Thomas Niel
Much of the upside from flagship drug Vascepa is already priced into Amarin stock. Wait for a pullback before buying AMRN stock.
FDA approval of Vascepa in use for cardiovascular events just widened Amarin’s revenue potential. Amarin stock should have a banner 2020.
Amarin stock has been on fire in 2019, but the reaction to its latest news was discouraging. Is that a buying opportunity or a warning sign?
Pharmaceutical companies are always difficult investment propositions, and Amarin shares proved why with its perhaps unjustifiably hyped drug Vascepa.
Amarin is doubling its sales force for Vascepa, a cholesterol-fighting drug, as potential competitors await results from their own trials.
From Real Money
Navellier RatingsPowered by Portfolio Grader